NEW Late Breaking January 20, 2020
Substantially reduced registration fee (150 E) has been maintained for PhD students and post-docs after the deadline of 20 December.
After the success of our first edition, we are pleased to announce MicrobiotaMi 2020: three days of scientific sessions and multidisciplinary networking at the brand new Humanitas Congress Center in Milan 5th-7th February 2020.
The aim of this International meeting is to focus on the molecular mechanisms and interactions in health and disease conditions, including nutritional aspects, sensitization, gut-brain communication, aging, cancer, chronic inflammation, autoimmunity.
Motivation for the selection of this topic is that despite a huge increase in genomic, proteomic and metabolomics data that allowed to relate microbiota composition to health and disease of different organs, the molecular mechanisms by which bacteria, viruses and fungi communicate with the host organism remain largely unknown.
Researchers in the broad field of microbiota, from bench to bedside, and companies will meet in Milano to share their knowledge and to create new collaborations and technology transfer opportunities. The program is divided into:
seven core sessions
1. Microbiota and immune cells
2. Gut-liver-brain axis
3. Microbiota and Pathogens
4. Gut-bone marrow axis
5. Mucosal surface microbiota
6. Microbiota and immune system: from allergies to cancer
7. Global microbiota signatures and pathologies
In each of these sessions, presentations will be made by leading immunologists and clinicians who will give keynote lectures on state of the art advancements in differing areas of the same microbiome field. A final round table for each session will discuss future development in that area, encouraging contributions from the audience.
MicrobiotaMi is characterized by a multidisciplinary approach, an outstanding scientific level, and a large active participation of young, early stage researchers. We anticipate the attendance of researchers from academia, clinical departments as well as biotech and pharma industries who are interested in the molecular, immunological and translational aspects of microbiota.[/tm_pb_cta]